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Sgeneration WATCHMAN LAA closure device. Of the 36 patients, the new device
was implanted in 34 (94.4%). In two patients (5.6%), device closure was attempted
but unsuccessful due to an unfavorable LAA anatomy (early separation into multiple
lobes in one and acute LAA angulation in the second). In these cases closure was
performed successfully with a different closure system. Though in eight patients
partial and in fourteen full recaptures were needed prior to ﬁnal release, there was no
pericardial effusion. Mean procedural time was 50  45 minutes. No device-related
adverse events occurred during the procedure and accurate device placement was
achieved in all implanted patients. During the follow-up of 12 months, three
ischemic strokes (8.3%), one hemorrhage stroke (2.7%), one TIA (2.7%) and three
deaths (8.7%) occurred. Device-associated thrombus formation was seen in one
patient (2.7%) at the six-month follow-up treated with low molecular weight
heparin.
Conclusions: LAA closure with the newer (fourth) generation WATCHMAN device
is feasible and safe. The atraumatic distal end may reduce the incidence of pericardial
effusion during implantation.
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Background: Recent study results present left atrial appendage (LAA) occluders as
an alternative to oral anticoagulation for stroke prevention in patients with atrial
ﬁbrillation. Several devices with different designs (speciﬁcally different anchoring
methods and diameters) are being tested in clinical and animal trials with good results.
Device anchoring and achieving sufﬁcient seal remain challenges, considering the
diverse morphologies of the LAA, but must be achieved in order to prevent residual
ﬂow and possible associated thrombotic events. There are currently no standard
guidelines or norms for in-vitro assessment and comparability of LAA occluders and
their function.
Methods: In order to design a test system for the in-vitro assessment of LAA
occluder function, a design study and review of literature and CT-data were per-
formed. Additionally, anatomical studies on LAAs of porcine hearts were performed
to better incorporate the surface structure and mechanical properties into the test
setup.
Results: A modular in-vitro test system with the possibility of integrating exact
physiological models of the LAA was developed. The system allows for integration
and exchange of different LAA morphologies cast from silicone or native animal
anatomies and has the possibility to assess permeability, seal and anatomical ﬁt of
LAA occluders.
Conclusions: Standardized tests are essential during the establishment of novel device
based therapies, to ensure comparability and the fulﬁllment of basic requirements. The
in-vitro test setup for LAA occluders presented here allows for assessment and
optimization of LAA occluders.Mitral Valve Disease and Treatment
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Acute Hemodynamic effects of the MitraClip System. Focus on grade of MR,
stroke volume, LA-, PA- and PCW- pressure. Analyzing 330 MitraClip
procedures at the AK St. Georg, Hamburg
Thomas Thielsen1, Christian Frerker1, Felix Kreidel1, Hannes Alessandrini1,
Marco Marzullo1, Karl-Heinz Kuck1, Ulrich Schaefer1
1Asklepios Klinik St. Georg, Hamburg, Germany
Background: Hemodynamic changes after MitraClip procedure are rarely described
till today. Aim of this work was to improve the understanding of the acute hemo-
dynamic effects.
Methods: Till today more than 330 Patients have been treated with the MitraClip
System at the AK St. Georg in Hamburg. Hemodynamics have been evaluated with
Swan Ganz catheterization and thermodilution method directly before and after
Clipping. The functional result was assessed 6 weeks, 6 months and 12 months after
the MitraClip procedure.B212 JACC Vol 62/18/Suppl B j October 27–NovemberResults: 314 out of 330(95.2%) patients could be treated successfully (MR post 2).
30 day mortality was 7%. MR was reduced signiﬁcantly from 3.0(0.3) to 1.1(1.1)
(p<0.001), needing an average of 1.4 Clips(0.6). Cardiac output(CO) increased
from 3.7l/min(1.1) to 4.7l/min(1.3) directly after the procedure (p<0.001). Stroke
volume(SV) increased from 62.4ml(18.7) to 80.7ml(26.9) (p<0.001). Systolic
pulmonary artery pressure (PAPs) increased slightly from 39.9mmHg(12.5) to
42.2mmHg(12.2) (p<0.05). Wedge pressure (PCWP, mean) fell from
16.8mmHg(7.8) before to 15.7mmHg(6.5) post MitraClip (p<0.05). Left atrial
pressure (LA, mean) was reduced signiﬁcantly (p<0.001) from 16.1mmHg(6.9) to
13.2mmHg(6.1). Grade of dyspnea by NYHA fell signiﬁcantly as well (3.2(0.5)
baseline, 2.1(0.7) after 6 months and 2.2(0.6) after 12 months), p<0.001. Grade of
MR assessed by echo was reduced stable and signiﬁcantly from 3.1(0.3) before to
1.1(0.6) directly after and 1.8(0.7) after 6 months, p<0.001.
Conclusions: The MitraClip procedure shows a stable reduction of MR combined
with a stable improvement of the clinical symptom dyspnea. We’ve shown that this
non open chest treatment of MR improves the CO and SV of up to 27% while
reducing LA pressure signiﬁcantly. If these ﬁndings have a prognostic impact is part
of running investigation.
TCT-695
A Gender-Speciﬁc Look at MitraClip Therapy in Surgical High-Risk Patients:
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Background: In Europe, MitraClip (MC) therapy for signiﬁcant mitral regurgitation
(MR) is increasingly being performed, particularly in elderly patients at high surgical
risk. Outcomes emphasizing differences between men and women are lacking. We
present a high-volume single-center retrospective analysis of outcomes according to
gender.
Methods: By 01/2013, 361 consecutive patients (75  9 years, 227 men [M; 63%],
134 women [F; 37%]) with MR 3+/4+ had undergone MC therapy at the University
Heart Center Hamburg. All patients were adjudicated by heart team consensus as not
amenable to surgery.
Results: Baseline conditions were signiﬁcantly more adverse in M than in F, with
higher log. EuroSCORE, lower LVEF, and higher prevalence of cardiomyopathy,
hypercholesterolemia, diabetes, coronary artery disease, renal failure, and functional
MR in the former. Procedures were successful (discharge MR 2+) in 207 M (91%)
and 118 F (88%, p¼NS). Follow-up information was available in 205 M (90%) and
116 F (87%) at a median of 12.7 (range, 0.3-41) and 13.6 (0.4-39) months, respec-
tively (p¼NS). No signiﬁcant differences in the prevalence of MR 2+ and of NYHA
functional class II were observed at 12 months (MR: M 91%, F 85%; NYHA: M
60%, F 50%) and 24 months (MR: M 91%, F 80%; NYHA: M 62%, F 49%). Overall,
cumulative survival was not different between M and F (p[logrank]¼0.12), but
survival curves diverged signiﬁcantly in favor of F after 12 months (p¼0.03 by
landmark analysis). Independent predictors of death on multivariate Cox regression
analysis were renal failure and MC failure in M, yet renal failure and dilated
cardiomyopathy in F. Rehospitalizations were frequent (M 54% and F 41% at 18
months), but not signiﬁcantly different between M and F. MC failure was predictive of
rehospitalizations in both genders.
Conclusions: MC therapy appears to be equally effective, acutely as well as in the
long term, in M and F at high surgical risk. Increased mortality after 1 year in M is
likely related to higher comorbidity and poorer LV function and requires further study.
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Background: The aim of this study is to investigate the predictors of quality of life
(QoL) restoration 1 year after MitraClip implantation in heart failure patients with
FMR in our single center experience.
Methods: From October 2008, 109 consecutive patients with FMR underwent
MitraClip implantation (mean age 699 years). FMR was ischemic in 75%. All
patients underwent standardized assessment of mitral valve anatomy and functional
status. Preprocedural QoL was assessed by Minnesota Living with Heart Failure
Questionnaire (MLHFQ). Logistic EuroScore was 2216%; 82% pts were in NYHA
class III-IV. Mean EF was 2811%; LVEDD was 688 mm. A cut-off of 14 points
with MLHFQ was used to deﬁne QoL restoration 1 year after the procedure (corre-
sponding to the mean MLHFQ observed in a NYHA I-II heart failure Italian pop-
ulation with mean age of 61 years).1, 2013 j TCT Abstracts/POSTER/Mitral Valve Disease and Treatment
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events included: IABP support (13%), renal replacement therapy (6%), infections
(3.6%). No cerebrovascular events or AMI occurred. Median length of hospital stay
was 5 days. At discharge, 87% patients had MR  2+. At 1 year months EF was
34.710.4% (p¼0.002 compared to baseline value). Actuarial survival at 1 year was
89.63%. Actuarial freedom from MR3+ at 1 year was 79.44%. At 1 year,
MLHFQ improved from 4015 to 2216 (p<0.0001). Complete QoL restoration at 1
year was achieved in 43% of the survivors. At multivariate analysis, preoperative
value of serum pro-BNP1600 pg/ml was identiﬁed as independent predictors of QoL
restoration at 1 year (OR 0.2; p¼0.03).
Conclusions:MitraClip therapy is a safe and effective therapeutic option for high-risk
patients with FMR, leading to clinical and QoL improvements. Higher pro-BNP levels
are associated with reduced likelihood of QoL restoration at 1 year.
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Background: The MitraClip device has been used as a percutaneous therapy for both
functional and degenerative mitral regurgitation (MR). However, the actual impact of
the etiology of MR on safety and efﬁcacy outcomes has not been well elucidated. We
aim to describe the differences in experience and outcomes with the MitraClip in both
functional and degenerative MR.
Methods: The MitraClip Asia-Paciﬁc Registry (MARS) registry is a multi-centre
registry involving 6 different centres in the Asia-Paciﬁc region (Singapore, Malaysia,
Australia), collecting information on patients with 3+ MR who have undergone the
MitraClip procedure. Primary efﬁcacy outcome measured was a reduction in MR to
2+ at 30 days. The safety outcomes was 30-day freedom from major adverse events
(MACE), including mortality, myocardial infarction, non-elective cardiac surgery for
adverse events, renal failure, transfusion of 2 units of blood, ventilation for >48 h,
septicaemia, and new onset of atrial ﬁbrillation.
Results: A total of 125 patients (age 71.811.9years, 79 males) were included. Sixty-
four (51.2%) patients had functional MR and 61 (48.8%) had degenerative MR. Thirty
one (48.4%) of functional MR patients had 2 clips inserted compared to 34 (56.7%)
degenerative MR patients (p¼0.375). Acute procedural success was similar in both
functional and degenerative MR (95.3% (61/64) vs 90.2% (55/61), p¼0.316). 71.9%
(46/64) of functional MR had a reduction in MR to 2+ at 30 days compared to
70.5% (43/61) of degenerative MR (p¼0.510). There was no signiﬁcant difference in
both 30-day MACE (7.8% (n¼5) vs 14.8% (n¼9), p¼0.264) as well as 30-day
mortality rates (4.7% (n¼3) vs 6.6% (n¼4), p¼0.713) between functional and
degenerative MR.
Conclusions: The MitraClip procedure has similarly good short-term efﬁcacy and
safety outcomes in the treatment of both functional and degenerative MR.
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Acute changes in mitral annular geometery after Mitraclip procedure in
functional and degenerative mitral regurgitation
Jonathan Yap1, Khung Keong Yeo1, Nadira Hamid1, Eric Lim1, Peter Ting1,
Hak Chiaw Tang1, See Hooi Ewe2, Zee Pin Ding1
1National Heart Centre Singapore, Singapore, Singapore, 2National Heart Centre
Singapore, s, s
Background: Percutaneous edge-to-edge mitral valve repair with the MitraClip
device has been shown to be effective in reducing the severity of mitral regurgitation
(MR), with resultant improvements in clinical outcomes. However, the actual changes
in mitral annular geometry has not been well described. We aim to describe the effects
of the MitraClip on the mitral annular geometry in both functional and degenerative
mitral regurgitation
Methods: 33 consecutive patients (age 7210 yr, 18 males) with 3+ MR, who
underwent MitraClip procedure, were assessed with 3D transesophageal echocardi-
ography before and immediately after the procedure. Specialised software (4D MV-
Assessment, TomTec, GmbH) was used to process the images to obtain the following
mitral annular parameters: anterior-posterior (AP) diameter, intercommissural diam-
eter, 3D circumference (3D-C), 3D area (3D-A) and sphericity index (ratio of AP to
intercommisural diameter).
Results: Thirteen (39.4%) patients had functional MR and 20 (60.6%) had degener-
ative MR. Twenty seven (81.8%) patients had a 2-grade reduction in MR while theJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrremainder had a 1-grade reduction. In patients with functional MR, there was
a signiﬁcant reduction in AP diameter (3.90.5 vs 3.50.4cm, p<0.001), inter-
commisural diameter (4.30.4 vs 3.90.5cm, p¼0.006), 3D-C (13.41.3 vs
12.61.3cm, p¼0.011) and 3D-A (13.72.8 vs 11.52.6cm2, p<0.001). There was
no signiﬁcant change in sphericity index. Similarly, in patients with degenerative MR,
there was a signiﬁcant reduction in AP diameter (3.80.6 vs 3.40.5cm, p<0.001),
intercommisural diameter (4.20.6 vs 3.70.5cm, p<0.001), 3D-C (13.41.9 vs
12.11.4cm, p<0.001) and 3D-A (13.53.8 vs 10.72.6cm2, p<0.001). There was
no signiﬁcant change in sphericity index. Comparing patients with functional vs.
degenerative MR, there was no signiﬁcant difference in the degree of change for all
the above parameters.
Conclusions: Percutaneous edge-to-edge mitral valve repair results in acute changes
in mitral annular geometry in both functional and degenerative MR. The actual impact
of these geometrical changes on procedural success and durability of MR reduction
requires further investigation.
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Background: MitraClip therapy is an emerging option for high-risk patients with
functional mitral regurgitation (FMR). We compare MitraClip outcomes in idiopathic
(ID) and ischemic (IS) MR.
Methods: From October 2008, 109 patients underwent MitraClip for FMR at our
Institution. All patients underwent a standardized prospective data collection
pathway.
Results: Patients were 27 ID (24.8%) and 82 IS (75.2%). Groups did not differ in
age (p¼0.13), NYHA (p¼0.16) and pro-BNP (p¼0.47). ID were slightly "lower-
risk" due to less comorbidities: STS mortality 8.2% vs 11.5% (p¼0.06), REDO
3.2% vs 40.7% (p¼0.0004), COPD 11.1% vs 32.9 (p¼0.02), mean creatinine
1.30.5 vs 1.650.9 mg/dL(p¼0.04), inotropic support(0% vs 9.7%, p¼0.03). ID
however had a more impaired QoL (mean MLHFQ 4816 vs 3713, p¼0.0008;
SF36-F 297 vs 358, p¼0.004; SF36-M 389 vs 399; 6MWT 16876 vs
202109 m, p¼0.08) and a deeper heart dysfunction: mean EF 249% vs
3011%, p¼0.02; EDD 697 vs 678 mm(p¼0.20). Implantation was successful
in 100% vs 98.8%(p¼0.56) and multiple clips were used in 77.8% vs 67.1%
(p¼0.19) of ID and IS respectively. Residual MR>2 was 11% vs 7.5% (p¼0.26).
There was no difference in procedural time, post-operative length of stay and
complications (all p>0.05). In-hospital mortality was 0% in ID vs 2 in IS patients
(p¼0.41). Twenty-two ID and 64 IS reached 1-year follow-up: survival was 86.4%
vs 90.6% (p¼0.57), MR2 78% vs 80% (p¼0.81) respectively. Similar outcomes
were also observed regarding NYHA (18% vs 9%, p¼0.26), MLHFQ (2617 vs
2117, p¼0.16), SF36-F (4111 vs 449, p¼0.14), SF36-M (4711 vs 4810,
p¼0.30) and 6MWT (33694 vs 32978, p¼0.59). All improvements were
statistically signiﬁcant compared to baseline, both in ID and IS (all p<0.05). At 1
year ID and IS had similar EDD (6610 vs 638, p¼0.21), but improvement
appeared signiﬁcant only in the IS (p¼0.19 vs p¼0.0004). EF recovery was also
reduced in the ID vs IS (266 vs 3611, p¼0.0016; respectively p¼0.13 and
p¼0.0036 against baseline).
Conclusions: MitraClip in ID is safe and effective in MR reduction and symptoms
relief at 1-year, providing similar outcomes compared to IS. Ventricle remodeling and
EF recovery however appear to be reduced in the ID setting.TCT-700
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Background: MitraClip therapy is emerging as a viable option for high-risk patients.
The aim of the study was to assess MitraClip and surgical repair results in octoge-
narians with degenerative mitral regurgitation (DMR).
Methods: Since October 2008, 46 octogenarians underwent isolated mitral repair for
DMR at our Institution using MitraClip or standard surgery. A retrospective
comparison was conducted.
Results: MitraClip was performed in 24 (52.2%) and surgery in 22 (44.8%) cases.
Baseline features for MitraClip and surgery respectively included: mean age 84.73.4
vs 81.81.6 years (p¼0.0004), median STS mortality 8.4 vs 5.7 (p¼0.02), NYHA>II
70.8% vs 40.9% (p¼0.04), mean creatinine 1.20.3 vs 0.90.3 mg/dL (p¼0.009),
chronic obstructive pulmonary disease 33% vs 9% (p¼0.04). The groups did not differacts/POSTER/Mitral Valve Disease and Treatment B213
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